[xoo_el_inline_form active="login"]
CytoArm’s Armed-T Platform
Solves Major Challenges of T cell therapy
CytoArm addresses these critical challenges with its Armed-T platform. Instead of relying on viral vectors, our platform employs bi-functional antibodies (BsAb), which use a much smaller amount of antibody compared to traditional antibody drugs. This lower concentration minimizes the impact on the human body, reducing the risk of severe side effects, and providing a safer, more controllable therapy.
The Challenges of Current T Cell Therapies Armed-T Platform Solves
Modern T cell therapies have shown immense potential in treating various cancers, but they come with significant challenges.
◆ Oncogenic Risk: The primary issues is the use of viral vectors for gene editing that may couse oncogenic potential, where the virus may unintentionally activate cancer-causing genes, leading to serious health concerns. By avoiding viral vectors, we eliminate the potential for viral-based oncogenesis, a significant safety concern in gene therapies.
◆ Cost-Intensive QC: This viral approach often requires large financial investments in quality control (QC) due to the inherent risks associated with using viruses. Our non-viral approach significantly reduces the need for costly quality control processes typically required for viral-based therapies.
◆ Difficult to Manage Side Effects: If side effects occur, current T cell therapy can be extremely difficult to manage or reverse. These high concentrations and genetic modifications can lead to unpredictable, long-term consequences for patients. With an extremely lower antibody concentration, the risk of long-lasting side effects is minimized, making our therapy far safer and easier to manage.
◆ Cost-Intensive QC: This viral approach often requires large financial investments in quality control (QC) due to the inherent risks associated with using viruses. Our non-viral approach significantly reduces the need for costly quality control processes typically required for viral-based therapies.
◆ Difficult to Manage Side Effects: If side effects occur, current T cell therapy can be extremely difficult to manage or reverse. These high concentrations and genetic modifications can lead to unpredictable, long-term consequences for patients. With an extremely lower antibody concentration, the risk of long-lasting side effects is minimized, making our therapy far safer and easier to manage.
Advantages of CytoArm’s Armed-T Platform:
The Armed-T platform brings a revolutionary approach to T cell therapies, offering several key advantages:
CytoArm’s Armed-T platform addresses these challenges head-on, offering significant advantages over traditional T-cell therapies:
✔ High Purity: Our innovative Armed-T technology ensures that T-cell products are manufactured with a purity level exceeding 90%. This high purity enhances the safety and efficacy of the therapy, leading to more consistent and reliable patient outcomes.
✔ High Adaptability: The Armed-T platform is designed to be highly adaptable, allowing it to target a broad range of cancers and autoimmune diseases. By equipping T cells with bi-functional antibodies (BsAbs), our technology can be tailored to address over 50 different diseases, providing treatment options for patients with various types of cancers.
✔ Virus-Free Production: Unlike traditional T-cell therapies that rely on viral vectors, Armed-T uses a non-viral approach, reducing the risk of off-target effects and improving the overall safety of the therapy.
✔ Rapid Massive Manufacturing: CytoArm’s platform enables rapid production within just 10 days, significantly faster than traditional methods. This quick turnaround ensures that patients receive timely treatment, which is critical in combating aggressive cancers.
✔ High Purity: Our innovative Armed-T technology ensures that T-cell products are manufactured with a purity level exceeding 90%. This high purity enhances the safety and efficacy of the therapy, leading to more consistent and reliable patient outcomes.
✔ High Adaptability: The Armed-T platform is designed to be highly adaptable, allowing it to target a broad range of cancers and autoimmune diseases. By equipping T cells with bi-functional antibodies (BsAbs), our technology can be tailored to address over 50 different diseases, providing treatment options for patients with various types of cancers.
✔ Virus-Free Production: Unlike traditional T-cell therapies that rely on viral vectors, Armed-T uses a non-viral approach, reducing the risk of off-target effects and improving the overall safety of the therapy.
✔ Rapid Massive Manufacturing: CytoArm’s platform enables rapid production within just 10 days, significantly faster than traditional methods. This quick turnaround ensures that patients receive timely treatment, which is critical in combating aggressive cancers.
English 
Chinese